CD34 PE-Cyanine7

Overview

CD34 PE-Cyanine7 is a Mouse monoclonal targeting CD34, supplied as a PE-Cyanine7 format for FC workflows. It supports measurement of Human target expression in common experimental systems.

Key elements and design rationale

• Clone: CBI.212 — consistent clone identity can support panel reproducibility and cross-study comparisons.
• Isotype: IgG1, k — informs selection of matched controls and secondary reagents when relevant.
• Conjugate: PE-Cyanine7 — enables direct detection in fluorescence-based assays. Excitation is typically matched to Yellow (561nm) lasers in cytometer configurations.
• Host species: Mouse — useful for panel design and control strategy planning.
• Reactivity: Human — interpret staining in the context of species-specific sequence and expression differences.

Key specifications such as clone identity, isotype, and fluorophore conjugation help researchers align panel design, control selection, and instrument configuration with the biological question and sample type.

Biological background

CD34, also known as gp105-120, is a type I monomeric sialomucin-like glycophosphoprotein with a molecular weight of approximately 105-120 kDa. It is primarily expressed on hematopoietic stem and progenitor cells, bone marrow stromal cells, capillary endothelial cells, embryonic fibroblasts, and certain nervous tissues. CD34 is widely used as a marker to identify human hematopoietic stem and progenitor cells. Its expression varies with differentiation stages, being highly expressed on early progenitor cells and gradually decreasing as cells mature, eventually becoming absent in fully differentiated hematopoietic cells. Functionally, CD34 plays a role in cell adhesion and lymphocyte homing by binding to L-selectin and E-selectin ligands. It is found on all hematopoietic colony-forming cells in bone marrow and blood, including both unipotent (CFU-GM, BFU-E) and pluripotent progenitors (CFU-GEMM, CFU-Mix, and CFU-Blast). CD34+ cells that are uncommitted lack lineage-specific markers such as CD71, CD33, CD10, and CD5, whereas lineage-committed CD34+ cells express CD38 at high levels. Additionally, most CD34+ cells express either CD45RO or CD45RA, with CD45RO+ cells being the more primitive subset. CD34 is also present on early myeloid cells expressing CD33 but lacking CD14 and CD15, as well as early erythroid cells that express CD71 and dimly express CD45. It is absent in normal peripheral blood lymphocytes, monocytes, granulocytes, and platelets. Clinically, CD34 is expressed in approximately 60% of acute B-lymphoid leukemias and acute myeloid leukemias (AML), as well as in a small percentage (1-5%) of acute T-lymphoid leukemias. However, it is not found in chronic lymphoid leukemias or lymphomas.

Research relevance and current trends

• High-parameter immunophenotyping: combining CD34 with complementary lineage and activation markers to resolve complex cell states.
• Panel standardization and data comparability: increasing emphasis on consistent reagents, compensation-aware fluorophore choices, and shared gating strategies.
• Integration with single-cell multi-omics: pairing surface marker profiling with transcriptomic or proteomic readouts to connect phenotype to function.

Common research applications

• Flow cytometry: quantify CD34-positive populations and compare expression distributions across conditions or time points.
• Cell sorting: enrich CD34-defined subsets for downstream RNA/protein assays or functional readouts.

Changes in measured signal are typically interpreted in the context of cell subset frequency, activation/differentiation state, and sample processing effects rather than as a standalone readout.

Notes for experimental interpretation

• Fluorophore selection: consider brightness, spectral overlap, and instrument configuration; compensation and spillover can affect apparent population boundaries.
• Biology-driven confounders: activation state, differentiation, and isoform/PTM variation can shift epitope accessibility and apparent expression.
• Control concepts: include matched isotype and fluorescence-minus-one (FMO) controls where appropriate, and interpret results alongside biological positive/negative reference samples.

For antibody-based assays, monoclonal versus polyclonal format can influence epitope recognition breadth and signal consistency. Conjugated antibodies support direct detection and can simplify multicolor panel design when paired with appropriate controls and instrument settings.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.